Schultz, Stephanie A.
Gordon, Brian A.
Mishra, Shruti
Su, Yi
Morris, John C.
Ances, Beau M.
Duchek, Janet M.
Balota, David A.
Benzinger, Tammie L. S. http://orcid.org/0000-0002-8114-0552
Funding for this research was provided by:
Fred Simmons and Olga Mohan
Charles F. and Joanne Knight Alzheimer’s Research Initiative
Hope Center for Neurological Disorders
Mallinckrodt Institute of Radiology
American Society for Neuroradiology
Foundation for Barnes-Jewish Hospital
BJHF Paula and Rodger Riney Fund
BJHF Willman Scholar Fund
Daniel J Brennan Alzheimer Research Fund
BrightFocus Foundation (A2017272S, A2017330S)
Alzheimer’s Association Research Grant (AARG -17-532945)
Arizona Alzheimer’s Research Consortium
National Science Foundation (DGE-1745038)
National Institute on Aging (P50AG005681, R01AG055444, R01AG031581, UL1TR000448, R01EB009352, 1P30NS098577, K01AG053474-01A1)
National Institute on Aging (P01AG026276, P01AG003991)
Article History
First Online: 5 September 2019
Compliance with ethical standards
:
: John C. Morris, Tammie L.S. Benzinger, and Brian <i>A. Gordon</i> report participation in clinical trials sponsored by Eli Lilly, Roche, and Biogen. Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly provided doses of 18F-florbetapir, partial funding for 18F-florbetapir scanning, precursor for 18F-flortaucipir and technology transfer for manufacturing of 18F-flortaucipir). None of the authors, nor their family members, own stock or have equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.